UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $1.18 Million Stock Position in MBX Biosciences, Inc. $MBX

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of MBX Biosciences, Inc. (NASDAQ:MBX) by 194.9% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 21,344 shares of the company’s stock after buying an additional 14,106 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in MBX Biosciences were worth $1,178,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of MBX. Royal Bank of Canada raised its stake in MBX Biosciences by 59.6% during the fourth quarter. Royal Bank of Canada now owns 1,532 shares of the company’s stock worth $49,000 after acquiring an additional 572 shares in the last quarter. California State Teachers Retirement System boosted its stake in shares of MBX Biosciences by 64.7% in the 4th quarter. California State Teachers Retirement System now owns 1,754 shares of the company’s stock valued at $55,000 after purchasing an additional 689 shares in the last quarter. Strs Ohio boosted its stake in shares of MBX Biosciences by 128.6% in the 1st quarter. Strs Ohio now owns 1,600 shares of the company’s stock valued at $48,000 after purchasing an additional 900 shares in the last quarter. State of Wyoming bought a new stake in shares of MBX Biosciences during the 2nd quarter valued at approximately $58,000. Finally, The Manufacturers Life Insurance Company grew its holdings in shares of MBX Biosciences by 1.7% during the 4th quarter. The Manufacturers Life Insurance Company now owns 69,551 shares of the company’s stock valued at $2,155,000 after purchasing an additional 1,175 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Wall Street Zen downgraded shares of MBX Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Barclays reiterated an “overweight” rating and set a $88.00 price target on shares of MBX Biosciences in a report on Friday, August 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of MBX Biosciences in a research note on Friday, July 17th. UBS Group reissued a “buy” rating and set a $90.00 price objective on shares of MBX Biosciences in a report on Thursday, July 23rd. Finally, Mizuho boosted their price objective on MBX Biosciences from $57.00 to $91.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 29th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $77.00.

MBX Biosciences Price Performance

NASDAQ:MBX opened at $59.02 on Friday. MBX Biosciences, Inc. has a one year low of $9.63 and a one year high of $72.64. The company has a market cap of $2.84 billion, a PE ratio of -24.49 and a beta of 0.04. The firm’s 50 day simple moving average is $63.64 and its 200 day simple moving average is $44.66.

MBX Biosciences (NASDAQ:MBX) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.10). Equities research analysts expect that MBX Biosciences, Inc. will post -3.11 EPS for the current year.

MBX Biosciences Profile

MBX Biosciences, Inc is a clinical-stage biopharmaceutical company focused on developing precision peptide therapies for endocrine and metabolic disorders. The company uses its Precision Empowered Peptide platform to design peptide medicines intended to provide targeted biological activity, extended duration and improved dosing convenience.

MBX’s lead product candidate is MBX 2109, an investigational long-acting parathyroid hormone replacement therapy being developed for people with hypoparathyroidism.